- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04034693
Waitlist-Control Trial of Smartphone CBT for Body Dysmorphic Disorder (BDD)
April 26, 2021 updated by: Sabine Wilhelm, Koa Health B.V.
Smartphone Cognitive Behavioral Therapy for Body Dysmorphic Disorder: A Randomized, Waitlist-control Trial
The investigators are testing the efficacy of Smartphone-delivered cognitive behavioral therapy (CBT) treatment for body dysmorphic disorder (BDD).
The investigators hypothesize that participants receiving app-CBT will have greater improvement in BDD-YBOCS scores than those in the waitlist condition at treatment endpoint (week 12).
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The primary aim of this study is to test the efficacy of a Smartphone-based CBT treatment for adults with BDD recruited nationally.
In a prior study (Clinical Trials Identifier # NCT03221738), the investigators developed and pilot-tested the feasibility, acceptability, and preliminary efficacy of a CBT for BDD app in an open pilot trial.
The investigators are now further testing these outcomes in a randomized controlled trial.
Eligible subjects (N= 64) will be randomly assigned to 12-weeks of Smartphone-delivered CBT for BDD either immediately, or after a 12-week long waiting period (50/50 chance).
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- At least 18 years of age
- Current diagnosis of primary DSM-5 BDD, based on MINI
- Currently living in the United States
Exclusion Criteria:
- Psychotropic medication changes within 2 months prior to enrollment (Participants taking psychotropic medication must have been on a stable dose for at least 2 months prior to enrollment and not change medication during study period)
- Past participation in 4+ sessions of CBT for BDD
- Current severe substance use disorder
- Lifetime bipolar disorder or psychosis
- Acute, active suicidal ideation as indicated by clinical judgment and/or a score >2 on the suicidal ideation subscale of the C-SSRS.
- Current severe comorbid major depression, as indicated by clinical judgment and/or a QIDS-SR total score ≥ 21
- Concurrent psychological treatment
- Does not own a supported Smartphone with a data plan
- Lack of technology literacy that would interfere with ability to engage with smartphone treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Smartphone-delivered CBT for BDD
12-week Smartphone-delivered CBT for BDD.
|
12-week Smartphone-delivered CBT for BDD.
In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD.
The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
|
Other: 12 Week Waitlist Control
12 week waitlist control.
(Note: participants will be crossed over to 12-week Smartphone-delivered CBT for BDD following the 12-week waitlist control).
|
12-week Smartphone-delivered CBT for BDD.
In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD.
The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in BDD severity (BDD-YBOCS) at the end of treatment/waitlist period.
Time Frame: Endpoint (week 12)
|
The BDD Yale-Brown Obsessive Compulsive Scale (BDD-YBOCS) is the gold-standard, semi-structured clinician-administered assessment of BDD severity.
It contains 12 items ranging from 0 to 4, which are summed to generate a total score (range = 0 to 48).
Higher scores indicate more severe BDD symptoms.
The BDD-YBOCS will be used to assess change in BDD symptoms from baseline to endpoint.
|
Endpoint (week 12)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in depression at the end of treatment/waitlist period
Time Frame: Endpoint (week 12)
|
Participants who receive app-CBT will have greater improvement on depression (QIDS-SR).
The QIDS-SR is a self-report measure of depressive symptoms consisting of 16 scale items with responses ranging from 0 to 3, including one suicide item (item #12).
Higher scores correspond with greater depression severity, and the measure is a well-validated, sensitive measure of symptom severity in depression.
|
Endpoint (week 12)
|
Difference in functional impairment at the end of treatment/waitlist period
Time Frame: Endpoint (week 12)
|
Participants who receive app-CBT will have greater improvement on functional impairment (SDS).
The SDS uses a Likert scale from 0 (not at all) to 10 (extremely) to assess impairment in occupational, social, and family domains.
Higher scores indicate greater impairment.
|
Endpoint (week 12)
|
Difference in quality of life at the end of treatment/waitlist period
Time Frame: Endpoint (week 12)
|
Participants who receive app-CBT will have greater improvement on quality of life, assessed using The Quality of Life, Enjoyment, and Satisfaction Questionnaire - Short Form (Q-LES-Q).
The Q-LES-Q-SF is a self-report measure of subjective quality of life, containing Likert items ranging from 1 (Very Poor) to 5 (Very Good).
Total scores are presented as a percentage of the maximum value (i.e., ranging from 0 to 100, with higher scores indicating greater quality of life).
|
Endpoint (week 12)
|
Difference in delusionality at the end of treatment/waitlist period
Time Frame: Endpoint (week 12)
|
Participants who receive app-CBT will have greater improvement on delusionality, assessed using the Brown Assessment of Beliefs Scale (BABS).The BABS is a semi-structured, clinician-administered interview that assesses delusional thinking related to one's appearance concerns.
It contains 7 items ranging from 0-4, which are summed to generate a total score (range= 0-24).
Higher scores indicate greater delusionality.
|
Endpoint (week 12)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 12, 2019
Primary Completion (Anticipated)
January 15, 2022
Study Completion (Anticipated)
January 15, 2022
Study Registration Dates
First Submitted
July 24, 2019
First Submitted That Met QC Criteria
July 24, 2019
First Posted (Actual)
July 26, 2019
Study Record Updates
Last Update Posted (Actual)
April 28, 2021
Last Update Submitted That Met QC Criteria
April 26, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017P000293_B
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Body Dysmorphic Disorders
-
Karolinska InstitutetVastra Gotaland Region; Region Skane; Region StockholmRecruitingBody Dysmorphic DisordersSweden
-
Massachusetts General HospitalTelefónica S.A.CompletedBody Dysmorphic DisordersUnited States
-
Icahn School of Medicine at Mount SinaiTerminated
-
Institute of Psychiatry, LondonCompletedBody Dysmorphic DisorderUnited Kingdom
-
Massachusetts General HospitalCompleted
-
Westwood Institute for Anxiety Disorders, IncUnknownBody Dysmorphic DisordersUnited States
-
Karolinska InstitutetCompletedBody Dysmorhpic DisorderSweden
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoRecruiting
-
Florida State UniversityCompletedBody Dysmorphic DisorderUnited States
-
Massachusetts General HospitalCompletedBody Dysmorphic DisorderUnited States
Clinical Trials on Smartphone-delivered CBT for BDD
-
Massachusetts General HospitalKoa Health B.V.CompletedBody Dysmorphic DisorderUnited States
-
Massachusetts General HospitalKoa Health B.V.Not yet recruitingMajor Depressive DisorderUnited States
-
Massachusetts General HospitalKoa Health B.V.WithdrawnSocial Anxiety DisorderUnited States
-
Massachusetts General HospitalTelefónica S.A.WithdrawnMajor Depressive DisorderUnited States
-
Massachusetts General HospitalTelefónica S.A.WithdrawnObsessive-Compulsive DisorderUnited States
-
Institute of Psychiatry, LondonCompletedBody Dysmorphic DisorderUnited Kingdom
-
Massachusetts General HospitalKoa Health B.V.Completed
-
Brigham and Women's HospitalNational Psoriasis FoundationRecruitingPsoriasis | Depressive SymptomsUnited States
-
Karolinska InstitutetMassachusetts General Hospital; Hofstra UniversityCompleted
-
Linkoeping UniversityCompleted